Publications by authors named "Victoria Clapes"

Claim this Profile
C
CD200 genotype is associated with clinical outcome of patients with multiple myeloma.
Yolanda Gonzalez-Montes, Gemma Osca-Gelis, Rocío Rodriguez-Romanos, Alicia Villavicencio, Marta González-Bártulos, Victòria Clapes

Front Immunol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.
Yolanda Gonzalez-Montes, Rocío Rodriguez-Romanos, Alicia Villavicencio, Gemma Osca-Gelis, Marta González-Bártulos, Victòria Clapes

Front Immunol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.
David F Moreno, Victoria Clapés, Juan Alfons Soler, Yolanda González-Montes, Mercedes Gironella

Clin Lymphoma Myeloma Leuk· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting.
Maria Condom, Alberto Mussetti, Clara Maluquer, Rocío Parody, Eva González-Barca, Victòria Clapes

Cancer Rep (Hoboken)· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose intensity and treatment duration of bortezomib in transplant-ineligible newly diagnosed multiple myeloma.
Gladys Ibarra, Marta Peña, Laura Abril, Alicia Senín, Clara Maluquer

Eur J Haematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience.
Roser Velasco, Sarah Besora, Andreas A Argyriou, Cristina Santos, Rosó Sala

Anticancer Drugs· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to First Cycle Is the Major Predictor of Long-Term Response to Lenalidomide and Dexamethasone Therapy in Relapsed and Refractory Multiple Myeloma: Can We Spare Patients the Toxicity and Costs of Additional Agents?
Susanna Gassiot, Yolanda González, Mireia Morgades, Cristina Motlló, Victòria Clapés

Clin Lymphoma Myeloma Leuk· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma.
Raquel Jiménez-Segura, Miquel Granell, Mercè Gironella, Eugenia Abella, Antoni García-Guiñón

Eur J Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and efficacy of outpatient therapy with intermediate dose cytarabine, fludarabine and idarubicin for patients with acute myeloid leukaemia aged 70 or older.
Susana Vives, Albert Oriol, Sònia Piernas, Salut Brunet, Victòria Clapés

Eur J Haematol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Roser Velasco, Josep Petit, Victoria Clapés, Enric Verdú, Xavier Navarro

J Peripher Nerv Syst· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis